Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas Kraus is active.

Publication


Featured researches published by Thomas Kraus.


Journal of Clinical Investigation | 2005

Induction of mucosal tolerance in Peyer‘s patch—deficient, ligated small bowel loops

Thomas Kraus; Jens Brimnes; Christine Muong; Jianhua Liu; Thomas M. Moran; Kelly A. Tappenden; Peter Boros; Lloyd Mayer

To explore the requirement for M cells and the Peyers patch (PP) in induction of oral tolerance and address the potential in vivo role of intestinal epithelial cells as nonprofessional APCs, we have attempted to induce tolerance in mice with ligated small bowel loops without M cells and Peyers patches. A 2-centimeter section of vascularized small bowel was spliced away from the gut without disruption of the mesenteric attachments. We introduced OVA directly into the lumen of the loop prior to footpad immunization. By excising segments of bowel that contain PPs in some mice and segments without patches in others, we could study the necessity of the M cell and the underlying patch versus epithelial cells in induction of mucosal tolerance. We show that OVA-specific T cell proliferation and serum antibody responses are reduced in mice that have previously been given OVA both in PP-containing loops and in loops without patches. Furthermore, both high- and low-dose tolerance could be induced in the absence of PPs. Low-dose tolerance is associated with bystander suppression and requires IL-10, which indicates active suppression and the induction of regulatory cells. These data suggest that there is a critical role for components of the mucosal immune system other than PPs in antigen sampling and induction of oral tolerance.


American Journal of Reproductive Immunology | 2010

Peripheral Blood Cytokine Profiling During Pregnancy and Post-partum Periods

Thomas Kraus; Rhoda S. Sperling; Stephanie M. Engel; Yungtai Lo; Lisa Kellerman; Tricia Singh; Martine Loubeau; Yongchao Ge; Jose Luis Garrido; Marta Rodriguez-Garcia; Thomas M. Moran

Citation Kraus TA, Sperling RS, Engel SM, Lo Y, Kellerman L, Singh T, Loubeau M, Ge Y, Garrido JL, Rodríguez‐García M, Moran TM. Peripheral blood cytokine profiling during pregnancy and post‐partum periods. Am J Reprod Immunol 2010; 64: 411–426


Journal of Immunology | 2006

A Novel Role for Viral-Defective Interfering Particles in Enhancing Dendritic Cell Maturation

Jacob S. Yount; Thomas Kraus; Curt M. Horvath; Thomas M. Moran; Carolina B. López

Dendritic cell (DC) maturation is a crucial event in the development of adaptive immune responses that confer long-lasting protection against reinfection with the same virus. Sendai virus strain Cantell has a particularly strong ability to mature DCs independently of type I IFNs and TLR signaling, currently the best-described pathways for the induction of DC maturation. In this study, we demonstrate that defective-interfering (DI) particles present in Sendai virus-Cantell stocks are required for its robust DC maturation ability. DI particles contain incomplete genomes that are unable to replicate unless the viral polymerase is supplied by coinfection with complete virus. Accordingly, the improvement in the virus-induced maturation of DCs provided by DI particles requires standard virus coinfection and likely results from increased production of dsRNA replication intermediaries. This unique ability of DI particles to stimulate DC maturation cannot be mimicked by simply increasing the dose of standard virus. Furthermore, viruses with weak DC maturation abilities can be converted into potent DC stimulators with the addition of DI particles, supporting a potential application for DI particles as a novel natural adjuvant for viral immunizations.


Immunologic Research | 2012

The influence of pregnancy on systemic immunity.

Michael A. Pazos; Rhoda S. Sperling; Thomas M. Moran; Thomas Kraus

Adaptations in maternal systemic immunity are presumed to be responsible for observed alterations in disease susceptibility and severity as pregnancy progresses. Epidemiological evidence as well as animal studies have shown that influenza infections are more severe during the second and third trimesters of pregnancy, resulting in greater morbidity and mortality, although the reason for this is still unclear. Our laboratory has taken advantage of 20xa0years of experience studying the murine immune response to respiratory viruses to address questions of altered immunity during pregnancy. With clinical studies and unique animal model systems, we are working to define the mechanisms responsible for altered immune responses to influenza infection during pregnancy and what roles hormones such as estrogen or progesterone play in these alterations.


Hepatology | 2013

A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice

Juan E. Puche; Youngmin Lee; Jingjing Jiao; Costica Aloman; Maria Isabel Fiel; Úrsula Muñoz; Thomas Kraus; Tingfang Lee; Hal F. Yee; Scott L. Friedman

We have developed a novel model for depleting mouse hepatic stellate cells (HSCs) that has allowed us to clarify their contributions to hepatic injury and fibrosis. Transgenic (Tg) mice expressing the herpes simplex virus thymidine kinase gene (HSV‐Tk) driven by the mouse GFAP promoter were used to render proliferating HSCs susceptible to killing in response to ganciclovir (GCV). Effects of GCV were explored in primary HSCs and in vivo. Panlobular damage was provoked to maximize HSC depletion by combining CCl4 (centrilobular injury) with allyl alcohol (AA) (periportal injury), as well as in a bile duct ligation (BDL) model. Cell depletion in situ was quantified using dual immunofluorescence (IF) for desmin and GFAP. In primary HSCs isolated from both untreated wild‐type (WT) and Tg mice, GCV induced cell death in ∼50% of HSCs from Tg, but not WT, mice. In TG mice treated with CCl4+AA+GCV, there was a significant decrease in GFAP and desmin‐positive cells, compared to WT mice (∼65% reduction; P < 0.01), which was accompanied by a decrease in the expression of HSC‐activation markers (alpha smooth muscle actin, beta platelet‐derived growth factor receptor, and collagen I). Similar results were observed after BDL. Associated with HSC depletion in both fibrosis models, there was marked attenuation of fibrosis and liver injury, as indicated by Sirius Red/Fast Green, hematoxylin and eosin quantification, and serum alanine/aspartate aminotransferase. Hepatic expression of interleukin‐10 and interferon‐gamma was increased after HSC depletion. No toxicity of GCV in either WT or Tg mice accounted for the differences in injury. Conclusion: Activated HSCs significantly amplify the response to liver injury, further expanding this cell types repertoire in orchestrating hepatic injury and repair. (HEPATOLOGY 2013)


Journal of Clinical Immunology | 2012

Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study.

Thomas Kraus; Stephanie M. Engel; Rhoda S. Sperling; Lisa Kellerman; Yungtai Lo; Sylvan Wallenstein; Maria M. Escribese; Jose Luis Garrido; Tricia Singh; Martine Loubeau; Thomas M. Moran

PurposeThe increased risk of morbidity and mortality from certain microbial infections and the demonstrated improvements in the clinical course of some autoimmune diseases support the existence of pregnancy-related alterations in immune status. Elucidating the changes in innate and adaptive immunity during gestation may improve pregnancy outcomes and facilitate the development of targeted therapies for autoimmune diseases.MethodThe Viral Immunity and Pregnancy (VIP) study evaluated over 50 subjects longitudinally at three time points during pregnancy and at two time points post-delivery. Leukocyte enumeration was performed; functional responses of NK cells and CD4 T cells were analyzed, and soluble factors such as cytokines, defensins, and steroid hormones were measured in maternal blood.ResultsIn comparison to the post-partum period, the latter part of pregnancy was characterized by significant increases in blood phagocytes and pDCs and decreases in the number and activity of NK and T cells. Alterations were found in antimicrobial proteins and serum cytokines.ConclusionsThese data show that pregnancy is not a period of immunosuppression but an alteration in immune priorities characterized by a strengthening of innate immune barriers and a concomitant reduction in adaptive/inflammatory immunity in the later stages of pregnancy.


Experimental Hematology | 2013

Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap

Camelia Iancu-Rubin; Goar Mosoyan; Jiapeng Wang; Thomas Kraus; Victoria Sung; Ronald Hoffman

Red cell production is primarily determined by the action of erythropoietin. Additional erythropoiesis-regulatory factors include molecules and cellular interactions occurring within the bone marrow (BM) microenvironment. Sotatercept (ACE-011) is an activin receptor ligand trap that binds several members of the TGF-β superfamily. Treatment with ACE-011 reverses bone loss and reduces the degree of osteoporosis, but it is accompanied by elevated hemoglobin and hematocrit levels. The mechanisms underlying the beneficial effects of ACE-011 on red cell production remain unknown. This study explores the means by which ACE-011 promotes erythropoiesis. We showed that ACE-011 does not directly affect erythroid differentiation of human CD34(+) cells inxa0vitro. We next tested whether ACE-011 acts indirectly by affecting BM accessory cells. Conditioned media produced by BM stromal cells (SCs) inhibited erythroid differentiation of CD34(+) cells while maintained their ability to proliferate. However, conditioned media from SCs treated with ACE-011 partially restored erythropoiesis, coinciding with changes in the molecular and secretory profile of SCs, including the expression and secretion of erythropoiesis-modulatory factors. We conclude that inhibitory factors produced by BM SCs inxa0vitro might control erythropoiesis inxa0vivo and that agents that reverse these microenvironmental signals could provide an approach to attenuate anemia in clinical conditions.


Current Opinion in Gastroenterology | 2005

Oral tolerance and inflammatory bowel disease

Thomas Kraus; Lloyd Mayer

Purpose of review Oral tolerance refers to the ability of the mucosal immune system to actively inhibit systemic immune responses to fed antigens. Recently, clinical trials have used oral tolerance as a therapy for certain chronic inflammatory and autoimmune diseases such as multiple sclerosis and type I diabetes. Inflammatory bowel disease is now widely thought to be caused by the breakdown of oral tolerance through a combination of genetic and environmental factors. Therefore, it seems incongruous that clinicians would try to use oral tolerance therapy to alleviate the symptoms of inflammatory bowel disease. Yet, armed with the results of select animal models, trials have begun for oral tolerance therapy for Crohns disease. This review will outline the recent advances in understanding oral tolerance, explore the relation between oral tolerance and inflammatory bowel disease, and comment on the likelihood of successful oral tolerance therapy for inflammatory bowel disease. Recent findings The results of an oral tolerance trial in Crohns disease patients in Israel have shown some promising results, whereas the results of studies of experimentally induced oral tolerance in patients with inflammatory bowel disease from the authors laboratory have shown that feeding a neoantigen in an attempt to induce oral tolerance is not successful in patients with inflammatory bowel disease. Summary The fundamental difference in the mechanisms of oral tolerance in mice and humans requires a more focused effort to understand the human mucosal immune system before oral tolerance therapy for autoimmune and chronic inflammatory disorders reaches its full potential.


Obstetrics & Gynecology | 2012

Immunogenicity of Trivalent Inactivated Influenza Vaccination Received During Pregnancy or Postpartum

Rhoda S. Sperling; Stephanie M. Engel; Sylvan Wallenstein; Thomas Kraus; Jose Luis Garrido; Tricia Singh; Lisa Kellerman; Thomas M. Moran

OBJECTIVE: To estimate the effects of gestational age and other maternal factors on immunologic responses to influenza vaccination. METHODS: Antepartum and postpartum women receiving influenza vaccination as part of routine clinical care were enrolled through four consecutive vaccination seasons (starting October 2006 through January 2010). Immunologic responses to trivalent inactivated influenza vaccine and monovalent H1N1 were assessed as well as factors influencing vaccine responsiveness. Serum samples were obtained at baseline and 4–8 weeks postvaccination. RESULTS: Two hundred thirty-nine participants were included in the current analysis. Seroconversion rates to trivalent inactivated influenza vaccine strains were lowest in the first trimester (54.8%) and immediately postpartum (54.8%) and were highest in the late third trimester (69.6%) and late postpartum (69.4%); these differences were not statistically significant (P=.23). In a multivariable model, higher baseline antibody levels (P<.001) and prior year flu vaccination (P=.03) were both significantly associated with reduced odds of seroconversion. Overall, results were consistent when comparing trivalent inactivated influenza vaccine and monovalent pandemic H1N1 responses. Although there was overall no significant association between gestational age at vaccination (P=.23) or prepregnancy body mass index (P=.16), we observed somewhat lower rates of seroconversion for women vaccinated in the first trimester and for obese women. CONCLUSION: Adequate immunologic responses to inactivated influenza vaccines were demonstrated during pregnancy and the postpartum period. No diminution of immunogenicity was observed in the third trimester, a time of increased clinical vulnerability to influenza. LEVEL OF EVIDENCE: II


PLOS ONE | 2012

Estrogen Mediates Innate and Adaptive Immune Alterations to Influenza Infection in Pregnant Mice

Michael A. Pazos; Thomas Kraus; César Muñoz-Fontela; Thomas M. Moran

Pregnancy is a leading risk factor for severe complications during an influenza virus infection. Women infected during their second and third trimesters are at increased risk for severe cardiopulmonary complications, premature delivery, and death. Here, we establish a murine model of aerosolized influenza infection during pregnancy. We find significantly altered innate antiviral responses in pregnant mice, including decreased levels of IFN-β, IL-1α, and IFN-γ at early time points of infection. We also find reduced cytotoxic T cell activity and delayed viral clearance. We further demonstrate that pregnancy levels of the estrogen 17-β-estradiol are able to induce key anti-inflammatory phenotypes in immune responses to the virus independently of other hormones or pregnancy-related stressors. We conclude that elevated estrogen levels result in an attenuated anti-viral immune response, and that pregnancy-associated morbidities occur in the context of this anti-inflammatory phenotype.

Collaboration


Dive into the Thomas Kraus's collaboration.

Top Co-Authors

Avatar

Thomas M. Moran

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Lloyd Mayer

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Rhoda S. Sperling

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Kirk Sperber

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Houchu Chen

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Jens Brimnes

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Prarthana Beuria

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Tricia Singh

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Catherine Monk

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge